A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response

PURPOSE: Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed in 70–80% and in approxim...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Robbins, Paul F., Kassim, Sadik H., Tran, Thai Lan N., Crystal, Jessica S., Morgan, Richard A., Feldman, Steven A., Yang, James C., Dudley, Mark E., Wunderlich, John R., Sherry, Richard M., Kammula, Udai S., Hughes, Marybeth S., Restifo, Nicholas P., Raffeld, Mark, Lee, Chyi-Chia Richard, Li, Yong F., El-Gamil, Mona, Rosenberg, Steven A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361810/
https://ncbi.nlm.nih.gov/pubmed/25538264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2708
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky